Katharina Kieslich1,*, Jesse B. Bump2 , Ole Frithjof Norheim3 , Sripen Tantivess4 and Peter Littlejohns1 1 Faculty of Life Sciences & Medicine, Division of Health and Social Care Research, King’s College London, London, UK 2 Department of Global Health and Population, Harvard T. H. Chan School o

GIULIA GRECOa,*, PAULA LORGELLYb and INTHIRA YAMABHAIc a London School of Hygiene & Tropical Medicine, London, UK b Centre for Health Economics, Monash University, Melbourne, Victoria, Australia c Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangko

K. Chittawatanarat a, *, K. Tosanguan b, U. Chaikledkaew b, c, S. Tejavanija d, Y. Teerawattananon b a Division of Trauma and Critical Care, Department of Surgery, Faculty of Medicine, Maharaj Nakorn Chiang Mai Hospital, Intawarorod Road, Sripume, Chiang Mai University, Chiang Mai 50200, Thailand

Abstract Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care’s benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impac

Abstract Background Antimicrobial resistance (AMR) is accelerated by the widespread and often indiscriminate use of antimicrobials in humans, animals, and the environment. In 2015, the World Health Organization recognised AMR as one of the top ten global health threats, due to its potential to n

Generic reference cases for economic evaluation (EE) of “cure-based” health technologies may not fit into the new healthcare paradigm of precision medicine (PM). Current EE approaches were challenged by the complex evolving decision space of PM, lack of clinical evidence due to small patient cluster

Introduction Genetic disorders in children contribute to acute hospitalizations and mortality. Early diagnosis is critical for better outcomes but difficult to achieve due to atypical presentations for thousands of potential genetic diseases. Next-generation sequencing (NGS) is a precision

About the study Objective: This study aimed to quantify heterogeneity in the value for money of precision medicine (PM) by application types across contexts and conditions and to quantify sources of heterogeneity to areas of particular promises or concerns as the field of PM moves forward. Methods

Highlights Economic evidence (cost-effectiveness information) can be used to inform policy-making process in supporting the movement towards universal health coverage. Published literature has focused on methods to set a cost-effectiveness threshold (CET) which can be used to guide the cost-eff

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m